Compare DAKT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | BBIO |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 14.4B |
| IPO Year | 1994 | 2019 |
| Metric | DAKT | BBIO |
|---|---|---|
| Price | $18.90 | $74.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 20 |
| Target Price | $26.00 | ★ $75.75 |
| AVG Volume (30 Days) | 395.9K | ★ 2.0M |
| Earning Date | 12-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $770,283,000.00 | $353,780,000.00 |
| Revenue This Year | $12.94 | $128.44 |
| Revenue Next Year | $7.16 | $76.14 |
| P/E Ratio | $128.40 | ★ N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $10.24 | $25.34 |
| 52 Week High | $24.38 | $75.24 |
| Indicator | DAKT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 68.19 |
| Support Level | $17.09 | $70.35 |
| Resistance Level | $21.28 | $75.10 |
| Average True Range (ATR) | 0.87 | 2.33 |
| MACD | 0.23 | -0.13 |
| Stochastic Oscillator | 44.13 | 98.77 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.